tPA Helpers in the Treatment of Acute Ischemic Stroke: Are They Ready for Clinical Use?

키워드

참고문헌 (101)

1. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group, "Tissue plasminogen activator for acute ischemic stroke", N Engl J Med, 333, pp.1581~1587 (1995)
2. Hacke W, "Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke", N Engl J Med, 359, pp.1317~1329 (2008)
3. Emberson J, "Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials", Lancet, 384, pp.1929~1935 (2014)
4. Lees KR, "Effects of alteplase for acute stroke on the distribution of functional outcomes: a pooled analysis of 9 trials", Stroke, 47, pp.2373~2379 (2016)
5. Goyal M, "Endovascular thrombectomy after largevessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials", Lancet, 387, pp.1723~1731 (2016)
6. Saver JL, "Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke", JAMA, 309, pp.2480~2488 (2013)
7. Jickling GC, "Hemorrhagic transformation after ischemic stroke in animals and humans", J Cereb Blood Flow Metab, 34, pp.185~199 (2014)
8. Shi ZS, "Early blood-brain barrier disruption after mechanical thrombectomy in acute ischemic stroke", J Neuroimaging, 28, pp.283~288 (2018)
9. Wang X, "Mechanisms of hemorrhagic transformation after tissue plasminogen activator reperfusion therapy for ischemic stroke", Stroke, 35(11 Suppl 1), pp.2726~2730 (2004)
10. Simard JM, "Brain oedema in focal ischaemia: molecular pathophysiology and theoretical implications", Lancet Neurol, 6, pp.258~268 (2007)
11. Kastrup A, "Early disruption of the blood-brain barrier after thrombolytic therapy predicts hemorrhage in patients with acute stroke", Stroke, 39, pp.2385~2387 (2008)
12. Wang W, "Hemorrhagic transformation after tissue plasminogen activator reperfusion therapy for ischemic stroke: mechanisms, models, and biomarkers", Mol Neurobiol, 52, pp.1572~1579 (2015)
13. Tsuji K, "Tissue plasminogen activator promotes matrix metalloproteinase-9 upregulation after focal cerebral ischemia", Stroke, 36, pp.1954~1959 (2005)
14. Montaner J, "Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke", Circulation, 107, pp.598~603 (2003)
15. Dirnagl U, "Pathobiology of ischaemic stroke: an integrated view", Trends Neurosci, 22, pp.391~397 (1999)
16. Fisher M, "New approaches to neuroprotective drug development", Stroke, 42(1 Suppl), pp.S24~S27 (2011)
17. Savitz SI, "Reconsidering neuroprotection in the reperfusion era", Stroke, 48, pp.3413~3419 (2017)
18. Fisher M, "Update of the stroke therapy academic industry roundtable preclinical recommendations", Stroke, 40, pp.2244~2250 (2009)
19. Albers GW, "Stroke Treatment Academic Industry Roundtable (STAIR) recommendations for maximizing the use of intravenous thrombolytics and expanding treatment options with intra-arterial and neuroprotective therapies", Stroke, 42, pp.2645~2650 (2011)
20. Switzer JA, "Matrix metalloproteinase-9 in an exploratory trial of intravenous minocycline for acute ischemic stroke", Stroke, 42, pp.2633~2635 (2011)
21. Powers WJ, "2018 Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association", American Stroke Association, 2018, pp.49, e46~e110
22. Amar AP, "Can adjunctive therapies augment the efficacy of endovascular thrombolysis? A potential role for activated protein C", Neuropharmacology, 134(Pt B), pp.293~301 (2018)
23. Seitz RJ, "The effect of combined thrombolysis with rtPA and tirofiban on ischemic brain lesions", Neurology, 62, pp.2110~2112 (2004)
24. Barreto AD, "Randomized, multicenter trial of ARTSS-2 (Argatroban With Recombinant Tissue Plasminogen Activator for Acute Stroke)", Stroke, 48, pp.1608~1616 (2017)
25. Lapchak PA, "Tumor necrosis factor-alpha is involved in thrombolytic-induced hemorrhage following embolic strokes in rabbits", Brain Res, 1167, pp.123~128 (2007)
26. Chen W, "Matrix metalloproteinases inhibition provides neuroprotection against hypoxia-ischemia in the developing brain", J Neurochem, 111, pp.726~736 (2009)
27. Mishiro K, "A broad-spectrum matrix metalloproteinase inhibitor prevents hemorrhagic complications induced by tissue plasminogen activator in mice", Neuroscience, 205, pp.39~48 (2012)
28. Shehadah A, "Combination treatment with low-dose Niaspan and tissue plasminogen activator provides neuroprotection after embolic stroke in rats", J Neurol Sci, 309, pp.96~101 (2011)
29. Liu SF, "Inhibition of NF-kappaB activation by pyrrolidine dithiocarbamate prevents in vivo expression of proinflammatory genes", Circulation, 100, pp.1330~1337 (1999)
30. Wang Z, "Early administration of pyrrolidine dithiocarbamate extends the therapeutic time window of tissue plasminogen activator in a male rat model of embolic stroke", J Neurosci Res, 96, pp.449~458 (2018)
31. Tan Z, "Bryostatin improves survival and reduces ischemic brain injury in aged rats after acute ischemic stroke", Stroke, 44, pp.3490~3497 (2013)
32. Tan Z, "Bryostatin extends tPA time window to 6 h following middle cerebral artery occlusion in aged female rats", Eur J Pharmacol, 764, pp.404~412 (2015)
33. Li Q, "Inhibition of tPA-induced hemorrhagic transformation involves adenosine A2b receptor activation after cerebral ischemia", Neurobiol Dis, 108, pp.173~182 (2017)
34. Won S, "Progesterone attenuates hemorrhagic transformation after delayed tPA treatment in an experimental model of stroke in rats: involvement of the VEGF-MMP pathway", J Cereb Blood Flow Metab, 34, pp.72~80 (2014)
35. Sowndhararajan K, "Neuroprotective and cognitive enhancement potentials of baicalin: a review", Brain Sci, 8, pp.E104~ (2018)
36. Chen H, "Baicalin attenuates blood-brain barrier disruption and hemorrhagic transformation and improves neurological outcome in ischemic stroke rats with delayed t-PA treatment: involvement of ONOO(-)-MMP-9 pathway", Transl Stroke Res, 9, pp.515~529 (2018)
37. dela Peña IC, "Granulocyte colony-stimulating factor attenuates delayed tPA-induced hemorrhagic transformation in ischemic stroke rats by enhancing angiogenesis and vasculogenesis", J Cereb Blood Flow Metab, 35, pp.338~346 (2015)
38. Dela Peña IC, "Extension of tissue plasminogen activator treatment window by granulocyte-colony stimulating factor in a thromboembolic rat model of stroke", Int J Mol Sci, 19, pp.E1635~ (2018)
39. Zhang Z, "Adjuvant treatment with neuroserpin increases the therapeutic window for tissue-type plasminogen activator administration in a rat model of embolic stroke", Circulation, 106, pp.740~745 (2002)
40. Cai Y, "TGF-β1 prevents blood-brain barrier damage and hemorrhagic transformation after thrombolysis in rats", Exp Neurol, 266, pp.120~126 (2015)
41. Brundula V, "Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis", Brain, 125(Pt 6), pp.1297~1308 (2002)
42. Murata Y, "Extension of the thrombolytic time window with minocycline in experimental stroke", Stroke, 39, pp.3372~3377 (2008)
43. Fan X, "Effects of minocycline plus tissue plasminogen activator combination therapy after focal embolic stroke in type 1 diabetic rats", Stroke, 44, pp.745~752 (2013)
44. Malhotra K, "Minocycline for acute stroke treatment: a systematic review and meta-analysis of randomized clinical trials", J Neurol, 265, pp.1871~1879 (2018)
45. Lampl Y, "Minocycline treatment in acute stroke: an open-label, evaluator-blinded study", Neurology, 69, pp.1404~1410 (2007)
46. Padma Srivastava MV, "Efficacy of minocycline in acute ischemic stroke: a single-blinded, placebo-controlled trial", Neurol India, 60, pp.23~28 (2012)
47. Sheng Z, "Efficacy of minocycline in acute ischemic stroke: a systematic review and meta-analysis of rodent and clinical studies", Front Neurol, 9, pp.1103~ (2018)
48. Blacker DJ, "Reducing haemorrhagic transformation after thrombolysis for stroke: a strategy utilising minocycline", Stroke Res Treat, 2013, pp.362961~ (2013)
49. Ike dela Peña, "Strategies to Extend Thrombolytic Time Window for Ischemic Stroke Treatment: An Unmet Clinical Need", 대한뇌졸중영문학회지, 19(1), pp.50~60 (2017), 대한뇌졸중학회
50. Ángel Chamorro, "Neuroprotectants in the Era of Reperfusion Therapy", 대한뇌졸중영문학회지, 20(2), pp.197~207 (2018), 대한뇌졸중학회
51. Romanos E, "Uric acid reduces brain damage and improves the benefits of rt-PA in a rat model of thromboembolic stroke", J Cereb Blood Flow Metab, 27, pp.14~20 (2007)
52. Amaro S, "Uric acid therapy prevents early ischemic stroke progression:a tertiary analysis of the URICO-ICTUS trial (efficacy study of combined treatment with uric acid and r-tPA in acute ischemic stroke)", Stroke, 47, pp.2874~2876 (2016)
53. Chamorro Á, "Uric acid therapy improves the outcomes of stroke patients treated with intravenous tissue plasminogen activator and mechanical thrombectomy", Int J Stroke, 12, pp.377~382 (2017)
54. Cimino M, "Statins: multiple mechanisms of action in the ischemic brain", Neuroscientist, 13, pp.208~213 (2007)
55. Lapchak PA, "The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor simvastatin reduces thrombolytic-induced intracerebral hemorrhage in embolized rabbits", Brain Res, 1303, pp.144~150 (2009)
56. Zhang L, "Atorvastatin extends the therapeutic window for tPA to 6 h after the onset of embolic stroke in rats", J Cereb Blood Flow Metab, 29, pp.1816~1824 (2009)
57. Montaner J, "Combination of thrombolysis and statins in acute stroke is safe: results of the STARS randomized trial (stroke treatment with acute reperfusion and simvastatin)", Stroke, 47, pp.2870~2873 (2016)
58. 허지회, "Effect and Safety of Rosuvastatin in Acute Ischemic Stroke", 대한뇌졸중영문학회지, 18(1), pp.87~95 (2016), 대한뇌졸중학회
59. Yamashita T, "Dissociation and protection of the neurovascular unit after thrombolysis and reperfusion in ischemic rat brain", J Cereb Blood Flow Metab, 29, pp.715~725 (2009)
60. Aoki J, "YAMATO study (tissue-type plasminogen activator and edaravone combination therapy)", Stroke, 48, pp.712~719 (2017)
61. Enomoto M, "Clinical effects of early edaravone use in acute ischemic stroke patients treated by endovascular reperfusion therapy", Stroke, 50, pp.652~658 (2019)
62. Rha JH, "The impact of recanalization on ischemic stroke outcome: a meta-analysis", Stroke, 38, pp.967~973 (2007)
63. Rubiera M, "Predictors of early arterial reocclusion after tissue plasminogen activator-induced recanalization in acute ischemic stroke", Stroke, 36, pp.1452~1456 (2005)
64. Saqqur M, "Clinical deterioration after intravenous recombinant tissue plasminogen activator treatment: a multicenter transcranial Doppler study", Stroke, 38, pp.69~74 (2007)
65. Zinkstok SM, "Early administration of aspirin in patients treated with alteplase for acute ischaemic stroke: a randomized controlled trial", Lancet, 380, pp.731~737 (2012)
66. Zhang L, "Adjuvant treatment with a glycoprotein IIb", IIIa receptor inhibitor increases the therapeutic window for low-dose tissue plasminogen activator administration in a rat model of embolic stroke, 2003, pp.107, 2837~2843
67. Straub S, "Siebler M. Systemic thrombolysis with recombinant tissue plasminogen activator and tirofiban in acute middle cerebral artery occlusion", Stroke, 35, pp.705~709 (2004)
68. Li W, "Safety and preliminary efficacy of early tirofiban treatment after alteplase in acute ischemic stroke patients", Stroke, 47, pp.2649~2651 (2016)
69. Jang IK, "In vivo thrombin inhibition enhances and sustains arterial recanalization with recombinant tissue-type plasminogen activator", Circ Res, 67, pp.1552~1561 (1990)
70. Morris DC, "Extension of the therapeutic window for recombinant tissue plasminogen activator with argatroban in a rat model of embolic stroke", Stroke, 32, pp.2635~2640 (2001)
71. Barreto AD, "The argatroban and tissue-type plasminogen activator stroke study: final results of a pilot safety study", Stroke, 43, pp.770~775 (2012)
72. Berekashvili K, "Safety and feasibility of argatroban, recombinant tissue plasminogen activator, and intra-arterial therapy in stroke (ARTSS-IA Study)", J Stroke Cerebrovasc Dis, 27, pp.3647~3651 (2018)
73. Joyce DE, "Gene expression profile of antithrombotic protein c defines new mechanisms modulating inflammation and apoptosis", J Biol Chem, 276, pp.11199~11203 (2001)
74. Griffin JH, "Activated protein C: biased for translation", Blood, 125, pp.2898~2907 (2015)
75. Griffin JH, "Activated protein C, protease activated receptor 1, and neuroprotection", Blood, 132, pp.159~169 (2018)
76. Shibata M, "Anti-inflammatory, antithrombotic, and neuroprotective effects of activated protein C in a murine model of focal ischemic stroke", Circulation, 103, pp.1799~1805 (2001)
77. Cheng T, "Activated protein C inhibits tissue plasminogen activatorinduced brain hemorrhage", Nat Med, 12, pp.1278~1285 (2006)
78. Wang Y, "An activated protein C analog with reduced anticoagulant activity extends the therapeutic window of tissue plasminogen activator for ischemic stroke in rodents", Stroke, 43, pp.2444~2449 (2012)
79. Lyden P, "Phase 1 safety, tolerability and pharmacokinetics of 3K3A-APC in healthy adult volunteers", Curr Pharm Des, 19, pp.7479~7485 (2013)
80. Lyden P, "Final results of the RHAPSODY trial: a multi-center, phase 2 trial using a continual reassessment method to determine the safety and tolerability of 3K3A-APC, a recombinant variant of human activated protein c, in combination with tissue plasminogen activator, mechanical thrombectomy or both in moderate to severe acute ischemic stroke", Ann Neurol, 85, pp.125~136 (2019)
81. Fu Y, "Fingolimod for the treatment of intracerebral hemorrhage: a 2-arm proof-of-concept study", JAMA Neurol, 71, pp.1092~1101 (2014)
82. Kraft P, "FTY720 ameliorates acute ischemic stroke in mice by reducing thrombo-inflammation but not by direct neuroprotection", Stroke, 44, pp.3202~3210 (2013)
83. Zhu Z, "Combination of the immune modulator fingolimod with alteplase in acute ischemic stroke: a pilot trial", Circulation, 132, pp.1104~1112 (2015)
84. Tian DC, "Fingolimod enhances the efficacy of delayed alteplase administration in acute ischemic stroke by promoting anterograde reperfusion and retrograde collateral flow", Ann Neurol, 84, pp.717~728 (2018)
85. Noh SJ, "SP-8203 shows neuroprotective effects and improves cognitive impairment in ischemic brain injury through NMDA receptor", Pharmacol Biochem Behav, 100, pp.73~80 (2011)
86. Noh SJ, "SP-8203 reduces oxidative stress via SOD activity and behavioral deficit in cerebral ischemia", Pharmacol Biochem Behav, 98, pp.150~154 (2011)
87. Kim WK, "Therapeutic efficacy and pharmacological mechanisms of sp-8203 for treatment of cerebral ischemia", Stroke, 46(Suppl 1), pp.ATP239~ (2015)
88. Ju C, "Extension of therapeutic time window of tissue plasminogen activator with sp-8203 combination therapy in rat embolic stroke models", European Stroke Journal, 1(1 Suppl), pp.581~ (2016)
89. Han J, "(-)-Epigallocatechin gallate protects against cerebral ischemia-induced oxidative stress via Nrf2", ARE signaling, 2014, pp.39, 1292~1299
90. Lim SH, "The functional effect of epigallocatechin gallate on ischemic stroke in rats", Acta Neurobiol Exp (Wars), 70, pp.40~46 (2010)
91. You YP, "Epigallocatechin gallate extends the therapeutic window of recombinant tissue plasminogen activator treatment in ischemic rats", J Stroke Cerebrovasc Dis, 25, pp.990~997 (2016)
92. Wang XH, "Epigallocatechin gallate extends therapeutic window of recombinant tissue plasminogen activator treatment for brain ischemic stroke: a randomized doubleblind and placebo-controlled trial", Clin Neuropharmacol, 40, pp.24~28 (2017)
93. Albers GW, "Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging", N Engl J Med, 378, pp.708~718 (2018)
94. Nogueira RG, "Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct", N Engl J Med, 378, pp.11~21 (2018)
95. Shi ZS, "Predictors of functional dependence despite successful revascularization in large-vessel occlusion strokes", Stroke, 45, pp.1977~1984 (2014)
96. Kawiorski MM, "Alberta Stroke Program Early CT Score applied to CT angiography source images is a strong predictor of futile recanalization in acute ischemic stroke", Neuroradiology, 58, pp.487~493 (2016)
97. Gilberti N, "Leukoaraiosis is a predictor of futile recanalization in acute ischemic stroke", J Neurol, 264, pp.448~452 (2017)
98. Hussein HM, "Occurrence and predictors of futile recanalization following endovascular treatment among patients with acute ischemic stroke: a multicenter study", AJNR Am J Neuroradiol, 31, pp.454~458 (2010)
99. 김병문, "Causes and Solutions of Endovascular Treatment Failure", 대한뇌졸중영문학회지, 19(2), pp.131~142 (2017), 대한뇌졸중학회[DOI]
100. Aoki T, "Blood-brain barrier disruption and matrix metalloproteinase-9 expression during reperfusion injury: mechanical versus embolic focal ischemia in spontaneously hypertensive rats", Stroke, 33, pp.2711~2717 (2002)
101. Warach S, "Evidence of reperfusion injury, exacerbated by thrombolytic therapy, in human focal brain ischemia using a novel imaging marker of early blood-brain barrier disruption", Stroke, 35(11 Suppl 1), pp.2659~2661 (2004)

관련 논문AI추천